Tovuti hii inatekeleza vipengele vya msingi kwa sasa na bado haiko tayari kwa matumizi ya wagonjwa.
Tovuti hii inatekeleza vipengele vya msingi kwa sasa na bado haiko tayari kwa matumizi ya wagonjwa.
Inalinda dhidi ya aina 13 za bakteria ya nimonia zinazosababisha nimonia, homa ya uti wa ubongo, na maambukizi ya damu.
Inalinda dhidi ya aina 13 za bakteria ya nimonia zinazosababisha nimonia, homa ya uti wa ubongo, na maambukizi ya damu.
Watoto wachanga na wadogo, watu wazima zaidi ya miaka 65, watu wenye kinga dhaifu ya mwili.
Pregnancy: Safe if indicated.
Pneumococcal vaccines (PCV, PPSV23) are inactivated and considered safe during pregnancy when indicated.
Not routinely recommended during pregnancy for healthy women.
Indicated for pregnant women with high-risk conditions (asplenia, immunodeficiency, chronic lung/heart/liver disease).
PPSV23 has more post-marketing safety data in pregnancy than PCV.
Neonatal pneumococcal disease is rare — maternal vaccination primarily benefits the mother.
Breastfeeding: Safe — no restrictions.
Pneumococcal vaccines are inactivated and safe during breastfeeding. No modification to breastfeeding schedule required.
Pediatric use:
PCV13/PCV15: routine infant immunization. Schedule: 2, 4, 6 months + booster at 12–15 months (3+1) or 2, 4 months + 12 months (2+1 in some countries).
PCV20 (Prevnar 20): approved from 6 weeks of age (US) — may simplify schedule.
PPSV23: not recommended <2 years (poor response to polysaccharide antigens). Used from 2 years for high-risk children after PCV series.
High-risk children (asplenia, immunodeficiency, cochlear implants): PCV + PPSV23 sequential regimen.
Pneumococcal conjugate vaccines have dramatically reduced invasive pneumococcal disease in children worldwide.
Geriatric use: Routinely recommended for ≥65 years.
All adults ≥65 years should receive pneumococcal vaccination (WHO, CDC/ACIP).
Simplified approach (US/ACIP 2023): PCV20 (Prevnar 20) — single dose.
Alternative: PCV15 (Vaxneuvance) followed by PPSV23 (Pneumovax) ≥8 weeks to 1 year later.
Immune response may be reduced in immunocompromised elderly, but clinical benefit remains significant.
Revaccination with PPSV23: one additional dose after 5 years for high-risk individuals who received PPSV23 before age 65.
| Kipimo | Chapa | Siku tangu iliyotangulia | Kipindi cha umri |
|---|---|---|---|
| Kipimo 1 | Prevnar 13 | — | 1 miezi+ (max: 2 miezi) |
| Kipimo 1 | Prevnar 13 | — | 60 miaka+ |
| Kipimo 2 | Prevnar 13 | 60d | 4 miezi+ (max: 4 miezi) |
| Kipimo 3 | Prevnar 13 | 60d | 6 miezi+ (max: 6 miezi) |
| Kipimo 4 | Prevnar 13 | 180d | 1 miaka+ (max: 1 miaka) |
Unajua chanjo unayohitaji? Vizuri. Hujui? Tuambie tu unaenda wapi — tutapata chanjo zinazofaa na kliniki. Bure, bila masharti.
Maudhui katika ukurasa huu ni kwa madhumuni ya habari na elimu pekee. Hayaundi ushauri wa kitabibu, utambuzi, au mapendekezo ya matibabu. Ikiwa una wasiwasi wa kiafya, wasiliana na mtaalamu wa afya aliyeidhinishwa. Medova si mtoa huduma za matibabu.
Masharti kamili ya matumizi